Covovax Covid-19 Vaccine

The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.

China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.

The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.

Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.

Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.

National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.

The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.

Members of America's influential Congressional Hispanic Caucus have urged US President Joe Biden to champion vaccine collaboration with India to bring an end to the COVID-19 pandemic.

India's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official sources said on Wednesday.

Serum Institute of India has sought permission from India's drug regulator to conduct a phase-3 study of its COVID-19 vaccine Covovax as a booster dose in adults, official sources said on Sunday.

Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine

Serum Institute of India on Tuesday expressed gratitude to the Union Health Ministry for granting Emergency Use Authorization for its COVID-19 vaccine Covovax.

The centre cleared two more vaccines today and one anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used during emergency.

The Serum Institute of India on Friday sought permission from the Drugs Controller General of India (DCGI) to manufacture COVID-19 vaccine Covovax for restricted use in emergency situations at its Manjari manufacturing site, official sources said.

Recruitment of volunteers for the phase 2/3 clinical trial of COVID-19 vaccine Covovax among children aged 2 to 17 years began on Sunday at the Hamdard Institute of Medical Sciences and Research In Delhi.

The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.

China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.

The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.

Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.

Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.

National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.

The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.

Members of America's influential Congressional Hispanic Caucus have urged US President Joe Biden to champion vaccine collaboration with India to bring an end to the COVID-19 pandemic.

India's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official sources said on Wednesday.

Serum Institute of India has sought permission from India's drug regulator to conduct a phase-3 study of its COVID-19 vaccine Covovax as a booster dose in adults, official sources said on Sunday.

Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine

Serum Institute of India on Tuesday expressed gratitude to the Union Health Ministry for granting Emergency Use Authorization for its COVID-19 vaccine Covovax.

The centre cleared two more vaccines today and one anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used during emergency.

The Serum Institute of India on Friday sought permission from the Drugs Controller General of India (DCGI) to manufacture COVID-19 vaccine Covovax for restricted use in emergency situations at its Manjari manufacturing site, official sources said.

Recruitment of volunteers for the phase 2/3 clinical trial of COVID-19 vaccine Covovax among children aged 2 to 17 years began on Sunday at the Hamdard Institute of Medical Sciences and Research In Delhi.